Results 91 to 100 of about 4,011 (178)

Tolerability and clinical efficacy of inhaled treprostinil in patients with group 1 pulmonary arterial hypertension

, 2018
Background: Treprostinil is a prostacyclin analogue that directly vasodilates pulmonary and systemic arterial vascular beds. The United States Food and Drug Administration approved inhaled treprostinil in July 2009 for the treatment of group 1 pulmonary ...
Cher Y. Enderby, Charles Burger
core   +1 more source

Acute myocardial infarction following inhaled treprostinil initiation

An 81-year-old man with a history of interstitial lung disease attributed to idiopathic pulmonary fibrosis, severe aortic stenosis, and stable coronary artery disease was started on inhaled treprostinil for pulmonary hypertension associated with ...
Sarah Medrek, Bilal Alqam
core   +1 more source

Efficacy and safety of treprostinil in pediatric pulmonary hypertension following fontan surgery: a real-world analysis

BMC Pediatrics
Introduction This study aimed to evaluate the efficacy and safety of treprostinil in managing pulmonary hypertension (PH) following Fontan surgery in children.
Mingjie Zhang, Xi Chen, Yahe Xu, Yijun Chen, Zhiyue Zhang, Jingru Zhou, Zhuoming Xu   +6 more
doaj   +1 more source

Treprostinil, a prostacyclin analog, ameliorates ischemia-reperfusion injury in rat orthotopic liver transplantation.

, 2011
Prostaglandins have been evaluated for their ability to reduce IRI after liver transplantation; however, poor stability, side effects and the inability to show a significant difference in primary endpoint have limited their clinical application ...
Yoshida, J, Humar, A, N. Ghonem, Starzl, TE, Venkataramanan, R, N. Murase, Ghonem, N, A. Humar, D.B. Stolz, Stolz, D B, R. Venkataramanan, J. Yoshida, T.E. Starzl, Murase, N   +13 more
core   +1 more source

Inhaled Treprostinil for the Treatment of Pulmonary Arterial Hypertension

, 2011
Pulmonary arterial hypertension is a progressive disease characterized by vascular proliferation and vasoconstriction of the small pulmonary arteries that eventually leads to right-sided heart failure and death.
Martha Kingman, Abby Poms
core   +1 more source

The effects of standardized intravenous treprostinil in pulmonary arterial hypertension patients after total cavo-pulmonary connection procedure

European Journal of Medical Research
Objective Total cavo-pulmonary connection (TCPC) is a palliative treatment for single ventricular malformations. For high-risk patients (preoperative mean pulmonary arterial pressure, mPAP > 15 mmHg), between the inhaled and oral targeted medications ...
Xiaofeng Wang, Shilin Wang, Ruihuan Shen, Zhongyuan Lu, Xu Wang   +4 more
doaj   +1 more source

Repurposing the prostaglandin analogue treprostinil and the calcium-sensing receptor modulator cinacalcet to revive cord blood as an alternate source of hematopoietic stem and progenitor cells for transplantation

Frontiers in Pharmacology
ObjectiveThe expanding field of hematopoietic cell transplantation (HCT) for non-malignant diseases, including those amenable to gene therapy or gene editing, faces challenges due to limited donor availability and the toxicity associated with cell ...
Michaela Prchal-Murphy, Julia Zehenter, Marlene Fischer, Anita Pirabe, Madeleine Themanns, Behnaz Afrashteh, Eva Maria Putz, Karoline Kollmann, José Basílio, José Basílio, Manuel Salzmann, Wolfgang Strohmaier, Günther Krumpl, Alex Farr, Veronika Sexl, Michael Freissmuth, Eva Zebedin-Brandl   +16 more
doaj   +1 more source

Early Experience of Treprostinil Dry‐Powdered Inhaler in Patients With Pulmonary Hypertension Related to Fibrosing Interstitial Lung Disease at a Tertiary Referral Center

Pulmonary Circulation
A dry powder inhaler (DPI) formulation of treprostinil was FDA‐approved in March 2022 for patients with pulmonary arterial hypertension or pulmonary hypertension associated with ILD (PH‐ILD).
Jordin L. Rice, Ann Randall, Darlene Kim, Vera Pillitteri, Tim Lahm, Zulma X. Yunt, Jeffrey J. Swigris, M. Patricia George   +7 more
doaj   +1 more source

Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease.

, 2005
STUDY OBJECTIVES: To assess the efficacy and safety of continuous subcutaneous infusion of treprostinil, a stable prostacyclin analogue, for treating pulmonary arterial hypertension (PAH) in patients with connective tissue disease (CTD).
Oudiz RJ, Rubin LJ, Barst RJ, Schilz RJ, Simonneau G., Rich S, GALIE', NAZZARENO   +6 more
core   +1 more source

Parenteral Treprostinil as an Effective Bridge to Lung Transplant in Patients with Severe Pulmonary Hypertension Associated with Interstitial Lung Disease. [PDF]

J Cardiovasc Dev Dis
Hopkins J, Gayen S.
europepmc   +1 more source